08:22 AM EST, 12/18/2024 (MT Newswires) -- Polyrizon ( PLRZ ) said Wednesday it has entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a European-based GMP-certified manufacturer, to supply clinical trial material for its PL-14 allergy blocker study expected to begin in 2025.

The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker, the company said.

Polyrizon ( PLRZ ) said the manufacturing site for the clinical trial material will meet US and European regulatory standards and provide high-quality development support for the 2025 trial.

Polyrizon ( PLRZ ) shares were 160% higher in premarket trading.